<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01347112</url>
  </required_header>
  <id_info>
    <org_study_id>10-008559</org_study_id>
    <secondary_id>10-008309</secondary_id>
    <nct_id>NCT01347112</nct_id>
  </id_info>
  <brief_title>Varenicline Treatment for Active Alcoholic Smokers</brief_title>
  <official_title>Varenicline Treatment for Active Alcoholic Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alcohol dependence is a significant and prevalent public health problem affecting
      approximately 4% of the U.S. adult population. Individuals with alcohol dependence actively
      seek treatment annually, and long-term alcohol abstinence varies from 40-60%. Because of the
      high smoking prevalence and trends toward heavier smoking, alcoholic smokers are at high risk
      for both morbidity and mortality related to alcohol consumption and tobacco dependence.
      Although several studies have evaluated pharmacotherapy for tobacco dependence in recovering
      alcoholic smokers, few have evaluated pharmacotherapy for tobacco dependence among currently
      drinking alcoholic smokers.

      Varenicline is the most effective medication currently available for treating tobacco
      dependence. While some randomized trials have included recovering alcoholics, active
      alcoholism has been an exclusion criteria for these trials. Thus, this proposal would be the
      first such clinical trial in currently drinking alcoholic smokers. In addition to helping
      smokers to stop smoking, varenicline has also been shown to reduce alcohol consumption in
      rats. The goal of this proposal is to explore the potential efficacy of varenicline for
      treating tobacco dependence and reducing drinking among alcohol dependent smokers.

      The investigators hypothesize that 12 weeks of treatment with varenicline, a partial
      nicotinic acetylcholine receptor agonist will be more effective than placebo in treating
      tobacco dependence and reducing nicotine withdrawal symptoms in currently drinking alcoholic
      smokers. The investigators will also explore whether varenicline has an effect on drinking
      behavior among currently drinking alcoholics. The investigators propose the following
      specific aims to test these hypotheses in 70 currently drinking alcoholic smokers recruited
      at the Mayo Clinic in Rochester, Minnesota.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Seventy smokers who are currently alcohol dependent will be enrolled to this study. If found
      to be study eligible they will be randomized to either active varenicline or placebo for 12
      weeks. During these two weeks, they will be seen either weekly or biweekly. At the end of
      treatment, they will be followed up for an addition 12 weeks. Their last study visit will be
      6 months after randomization.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prolonged Smoking Abstinence at End of 12 Weeks of Varenicline Treatment</measure>
    <time_frame>12 weeks</time_frame>
    <description>Prolonged smoking abstinence will be identified by a negative response to the question, &quot;Since 2 weeks after your TQD, have you smoked any tobacco, even a puff, for 7 consecutive days or at least once each week on 2 consecutive weeks?&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prolonged Abstinence at 24 Weeks</measure>
    <time_frame>week 24</time_frame>
    <description>Prolonged abstinence is identified by a negative response to the question, &quot;Since 2 weeks after your TQD, have you smoked any tobacco, even a puff, for 7 consecutive days or at least once each week on 2 consecutive weeks?&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heavy Drinking Days at End of Treatment</measure>
    <time_frame>week 12</time_frame>
    <description>Heavy drinking is defined as 5 standard alcohol drinks or greater for men and 4 standard alcohol drinks or greater for women. The number of heavy drinking days per month was determined using the timeline follow-back method.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Smoking</condition>
  <condition>Tobacco Dependence</condition>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>Varenicline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>varenicline 1.0 mg twice daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar Pil</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Varenicline look alike sugar pill twice daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>varenicline 1.0 mg dose, twice daily for 12 weeks</description>
    <arm_group_label>Varenicline</arm_group_label>
    <other_name>chantix</other_name>
    <other_name>champix</other_name>
    <other_name>varenicline tartrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>sugar pill twice daily for 12 weeks</description>
    <arm_group_label>Sugar Pil</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or non-pregnant female cigarette smokers 18-years-of-age or older and reporting
             smoking at least an average of 10 cigarettes per day for the past year;

          2. Subject is alcohol dependence based on DSM IV criteria as assessed by the
             Mini-International Neuropsychiatric Interview (MINI) and the physician investigator;3

          3. Subject is currently drinking alcoholic beverages as assessed by the physician
             investigator;

          4. Subject is a female subject of non-childbearing potential or a female subject of
             childbearing potential - who is using contraceptives and has a negative pregnancy test
             result;

          5. Subject must be able to complete all the study visits;

          6. Subject has the ability to participate fully in all aspects of the study and keep
             scheduled appointments;

          7. Subject must be in good general health as determined by medical history, physical exam
             and physician investigator;

          8. Subject must provide written informed consent to participate in the study;

        Exclusion Criteria:

          1. Subject is a female who is pregnant, lactating or likely to become pregnant during the
             trial and not willing to use an acceptable form of contraception during the medication
             phase, (for women of child-bearing potential, a pregnancy test will be performed prior
             to entry into the study and at the end of the medication phase);

          2. Subject has another household member in study;

          3. Known allergy to varenicline;

          4. Subject is currently (in previous 30 days) using other behavioral or pharmacologic
             tobacco cessation program (i.e., behavioral therapy, nicotine replacement therapy,
             clonidine, varenicline, bupropion SR, nortriptyline or doxepin) and unwilling or
             unable to discontinue use;

          5. Subject has an unstable medical condition as determined by the physician investigator;

          6. Subject describes having a medical history of: a) unstable angina; b) myocardial
             infarction within the past 3 months; c) coronary angioplasty or d) an untreated
             cardiac dysrhythmia;

          7. Subject has a personal history of renal failure or is on renal dialysis;

          8. Subject has a current moderate or severe depression as assessed by the Center for
             Epidemiologic Studies-Depression survey (CES-D) and physician investigator;

          9. Subject has, as defined by the Columbia Suicide Severity Rating Scale (C-SSRS) current
             non-specific suicidal thoughts, or have a lifetime history of a suicidal attempt
             (defined as &quot;potentially self-injurious act committed with at least some wish to die,
             as a result of act&quot;);

         10. Subject has current (past 30 days) major depressive disorder or has a history of
             another psychiatric disorder such as psychosis or bipolar disorder;

         11. Subject currently uses of other tobacco products (i.e. pipe, cigar, smokeless tobacco)
             within the past 30 days;

         12. Subject currently has cancer [excluding non melanoma skin cancer] not in remission
             (cancer free for 5 years or more);

         13. Subject currently has Type 1 diabetes;

         14. Subject has untreated hypertension or baseline systolic blood pressure &gt; 180 or
             diastolic &gt; 100;

         15. Subject is currently on treatment with another investigational drug (within 30 days of
             study entry);
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard D. Hurt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franciscan Skemp Hospital</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://doi.org/10.1016/j.drugalcdep.2017.11.017</url>
    <description>Varenicline for tobacco-dependence treatment in alcohol-dependent</description>
  </link>
  <results_reference>
    <citation>Hurt RT, Ebbert JO, Croghan IT, Schroeder DR, Hurt RD, Hays JT. Varenicline for tobacco-dependence treatment in alcohol-dependent smokers: A randomized controlled trial. Drug Alcohol Depend. 2018 Mar 1;184:12-17. doi: 10.1016/j.drugalcdep.2017.11.017. Epub 2018 Jan 2.</citation>
    <PMID>29324248</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2011</study_first_submitted>
  <study_first_submitted_qc>May 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2011</study_first_posted>
  <results_first_submitted>May 1, 2014</results_first_submitted>
  <results_first_submitted_qc>May 1, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 30, 2014</results_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Ivana Croghan</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>smoking</keyword>
  <keyword>tobacco dependence</keyword>
  <keyword>alcohol dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Varenicline</title>
          <description>varenicline 1.0 mg twice daily for 12 weeks
Varenicline: varenicline 1.0 mg dose, twice daily for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Sugar Pill</title>
          <description>Varenicline look alike sugar pill twice daily for 12 weeks
placebo: sugar pill twice daily for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intention to treat all randomized subjects included in study</population>
      <group_list>
        <group group_id="B1">
          <title>Varenicline</title>
          <description>varenicline 1.0 mg twice daily for 12 weeks
Varenicline: varenicline 1.0 mg dose, twice daily for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Sugar Pill</title>
          <description>Varenicline look alike sugar pill twice daily for 12 weeks
placebo: sugar pill twice daily for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.2" spread="11.9"/>
                    <measurement group_id="B2" value="38.8" spread="10.4"/>
                    <measurement group_id="B3" value="39.5" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>tobacco use</title>
          <units>cigarettes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.1" spread="7.5"/>
                    <measurement group_id="B2" value="21.6" spread="7.3"/>
                    <measurement group_id="B3" value="20.4" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Prolonged Smoking Abstinence at End of 12 Weeks of Varenicline Treatment</title>
        <description>Prolonged smoking abstinence will be identified by a negative response to the question, &quot;Since 2 weeks after your TQD, have you smoked any tobacco, even a puff, for 7 consecutive days or at least once each week on 2 consecutive weeks?”</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Varenicline</title>
            <description>varenicline 1.0 mg twice daily for 12 weeks
Varenicline: varenicline 1.0 mg dose, twice daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pil</title>
            <description>Varenicline look alike sugar pill twice daily for 12 weeks
placebo: sugar pill twice daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Prolonged Smoking Abstinence at End of 12 Weeks of Varenicline Treatment</title>
          <description>Prolonged smoking abstinence will be identified by a negative response to the question, &quot;Since 2 weeks after your TQD, have you smoked any tobacco, even a puff, for 7 consecutive days or at least once each week on 2 consecutive weeks?”</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.034</p_value>
            <p_value_desc>1 tailed fisher's exact test</p_value_desc>
            <method>Fisher Exact</method>
            <method_desc>1 tailed</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prolonged Abstinence at 24 Weeks</title>
        <description>Prolonged abstinence is identified by a negative response to the question, “Since 2 weeks after your TQD, have you smoked any tobacco, even a puff, for 7 consecutive days or at least once each week on 2 consecutive weeks?”</description>
        <time_frame>week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Varenicline</title>
            <description>varenicline 1.0 mg twice daily for 12 weeks
Varenicline: varenicline 1.0 mg dose, twice daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pil</title>
            <description>Varenicline look alike sugar pill twice daily for 12 weeks
placebo: sugar pill twice daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Prolonged Abstinence at 24 Weeks</title>
          <description>Prolonged abstinence is identified by a negative response to the question, “Since 2 weeks after your TQD, have you smoked any tobacco, even a puff, for 7 consecutive days or at least once each week on 2 consecutive weeks?”</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.044</p_value>
            <p_value_desc>1 tailed fisher's exact</p_value_desc>
            <method>Fisher Exact</method>
            <method_desc>1 tailed</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heavy Drinking Days at End of Treatment</title>
        <description>Heavy drinking is defined as 5 standard alcohol drinks or greater for men and 4 standard alcohol drinks or greater for women. The number of heavy drinking days per month was determined using the timeline follow-back method.</description>
        <time_frame>week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Varenicline</title>
            <description>varenicline 1.0 mg twice daily for 12 weeks
Varenicline: varenicline 1.0 mg dose, twice daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Varenicline look alike sugar pill twice daily for 12 weeks
placebo: sugar pill twice daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Heavy Drinking Days at End of Treatment</title>
          <description>Heavy drinking is defined as 5 standard alcohol drinks or greater for men and 4 standard alcohol drinks or greater for women. The number of heavy drinking days per month was determined using the timeline follow-back method.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" spread="8.3"/>
                    <measurement group_id="O2" value="9.1" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.7</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
            <estimate_desc>data were analyzed using analysis of covariance with treatment as the independent variable and the baseline value included as the co-variate</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Varenicline</title>
          <description>varenicline 1.0 mg twice daily for 12 weeks
Varenicline: varenicline 1.0 mg dose, twice daily for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Sugar Pill</title>
          <description>Varenicline look alike sugar pill twice daily for 12 weeks
placebo: sugar pill twice daily for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>sleep disturbance</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>vivid dreams</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Richard Hurt</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-284-7313</phone>
      <email>rhurt@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

